Secondary Data Collection : To confirm the safety and effectiveness profiles under the actual medical practice of Vyndaqel in Japan. This study is conducted in accordance with the protocol even when Vynmac is used, and information the use of Vynmac during the observation period is also collected.
To comprehend information on the long-term safety (e.g., onset status of adverse reactions), etc. of patients who are treated with Vyndaqel for the treatment of transthyretin amyloid cardiomyopathy. When Vynmac is used, conduct the study to grasp information on safety (e.g., onset status of adverse reactions),etc. during the observation period.
Study Type
OBSERVATIONAL
Enrollment
1,214
The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if not tolerated.
The usual adult dose is 61 mg of tafamidis orally once daily.
Pfizer
Tokyo, Japan
The incidence of adverse drug reaction
Time frame: 30 months
Number of survival
Time frame: 30months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.